Teva Pharmaceuticals
Teva is the world's largest generic medicines company; its branded oncology products include omacetaxine (Synribo) for resistant chronic myeloid leukaemia, arsenic trioxide (Trisenox), bendamustine (Bendeka) and the G-CSF products Granix and Lonquex.
Overview
Teva acquired Cephalon in 2011, gaining Trisenox, Treanda and Synribo, and markets tbo-filgrastim (Granix) in the US and lipegfilgrastim (Lonquex) in Europe, alongside the largest generic oncology injectables portfolio worldwide.
Scorecard
All companies- approved products +18
- targets +2
- modalities +4
- regions +2
- registry trials +30
Filgrastim (Neupogen and its biosimilars) is a daily injection that speeds the recovery of infection-fighting white cells after chemotherapy, lets doctors give chemotherapy on schedule and mobilises stem cells for transplant.
Lipegfilgrastim (Lonquex) is a once-per-chemotherapy-cycle white cell booster used in Europe, similar to pegfilgrastim, for adults and children from two years old.
Omacetaxine (Synribo) is a twice-daily injection under the skin for chronic myeloid leukaemia that has stopped responding to at least two tyrosine kinase inhibitor pills.
Pages like this
not linked directly; found by shared links- ProductPegfilgrastim
Shares Lipegfilgrastim, Filgrastim (G-CSF).
- TechnologyGrowth factors: G-CSF and febrile neutropenia prevention
Shares Lipegfilgrastim, Filgrastim (G-CSF).